Exhibit 10.1Development AgreementThis Development Agreement (the “Agreement”) dated as of March 20, 2020 (the “Effective Date”) is entered into by and between CNSPharmaceuticals, Inc. (“CNS”), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, andWPD Pharmaceuticals, (“WPD”), a Polish corporation, having a business address of ul. Żwirki i Wigury 101, 02-089 Warszawa. CNS and WPD aresometimes referred to herein individually as a “Party” and collectively as the “Parties.”RECITALSWHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (“MBI”) (the “SublicenseAgreement”) to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use incertain territories;WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; andWHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights.NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration,the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows:ARTICLE 1DEFINITIONS1.1 “Approval Achievement Date” means the earlier of the: (i) date on which WPD receives marketing approval for a Development Productin one-half of the countries included in the Sublicensed Territory, as defined in the Sublicense Agreement; or (ii) the payment by WPD to CNS ofDevelopment Fees hereunder of 1.0 million.1.2 “Business Day” means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized orrequired to be closed in New York City, NY.1.3 “Calendar Quarter” means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31.1.4 “Confidential Information” includes: (1) all information contained in documents marked "confidential" and disclosed by one Party (the"disclosing party") to the other Party (the "recipient party") pursuant to this Agreement; (2) orally disclosed information which is disclosed by thedisclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as "confidential" and delivered to the recipientparty; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person wouldtreat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not theinformation is marked as “confidential.” Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNSdetermines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof.1.5 “Development Fee” means 50% of the Net Sales for any Development Products in the Development Territory.1.6 “Development Products” means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drugproducts for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for thetreatment of any viral infection in humans that is licensed between WPD and MBI after this date.1.7 “Development Territory” means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the SublicenseAgreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland.1Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/20201.8 “Net Sales” shall be defined in the same way as defined in Sections 6.1 (a)-(f) of the Sublicense Agreement, as applicable only to therelevant Development Products less any “pass-thru royalties” or “override royalty percentage” paid by WPD pursuant to the SublicenseAgreement.1.9 “Phase II Milestone Payment” means the completion by WPD of a Phase II Study in one of the countries included within theDevelopment Territory, which clinical trial meets all endpoints and is sufficient to form the basis of an application for approval of a DevelopmentProduct in one Development Territory other than Poland.1.10 “Sale”, “Sells”, “Sold” means the transfer or disposition of a Development Product, for value, to a person or entity for end use.ARTICLE 2DEVELOPMENT AGREEMENT2.1 Subject to the terms and conditions of this Agreement, WPD hereby agrees to use its commercially reasonable efforts in good faith totake, or cause to be taken, all actions, and to do or cause to be done, all things necessary, proper or desirable or advisable under applicable laws todevelop and commercialize the Development Products, with a goal of eventual approval of Development Products in the Development Territory. Inexchange for the payment by WPD of the Development Fee to CNS, CNS hereby agrees to pay WPD the following payments: (i) within thirtyBusiness Days from the date of this Agreement, CNS will make an upfront payment of 225,000 to WPD; and (ii) within thirty days of the verifiedachievement of the Phase II Milestone, (such verification shall be conducted by an independent third party mutually acceptable to the partieshereto), CNS will make a payment of 775,000 to WPD.2.2 If after three years from the Effective Date of this Development Agreement, WPD fails to use commercially reasonable efforts as setforth in section 2.1 above, CNS shall have the right to terminate this Agreement pursuant to the terms specified in Section 6.2 below, and CNS shallbe entitled to the return of any payments made hereunder. For the purpose of this clause, if WPD has expended the funds provided by CNSpursuant to section 2.1 above on developing anti-viral indications (including all direct and indirect costs of such development), it will be deemed tohave used commercially reasonable efforts in good faith.2.3 The first Development Fees payment shall be due forty-five days after the end of the Calendar Quarter in which the first Sale of aDevelopment Product took place. Thereafter, WPD shall furnish to CNS Development Fees no later than forty-five days after the end of eachCalendar Quarter for the Sale of Development Products through the end of such Calendar Quarter and shall further furnish CNS with a writtenstatement setting forth an accounting showing the calculation of the Development Fees.ARTICLE 3INFORMATION AND USE3.1 WPD shall furnish CNS with written reports summarizing the progress of the research and development conducted under theSublicense Agreement related to the Development Products on a quarterly basis.3.2 The Parties agree to a mutual exchange of any data, information or know-how resulting from the research and development of theDevelopment Products.ARTICLE 4OTHER COMPENSATION4.1 If MBI exercises its right to terminate the Sublicense Agreement in whole, or to remove a portion of the sublicensed subject matter thatrelates to some or all of the Development Products, by paying to WPD the Buyback Consideration (as defined in the Sublicense Agreement), WPDagrees that CNS shall receive the greater of (i) 50% of the Buyback Consideration that is attributable to the field of anti-viral pharmaceutical drugproducts for humans (such attribution to be mutually agreed upon by the Parties), and (ii) the amounts actually provided to WPD pursuant toSection 2.1 of this Agreement.2Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020ARTICLE 5CONFIDENTIALITY5.1 During the term of this Agreement and for a period of five (5) years thereafter, the Parties each agree that Confidential Information ofthe disclosing party, which is disclosed to the recipient party pursuant to this Agreement: (i) shall be received and held in strict confidence, (ii) shallbe used only for the purposes of this Agreement, and (iii) will not be disclosed by the recipient party (except as required by law, court order orregulation), its agents or employees without the prior written consent of the disclosing party, except to the extent that the recipient party canestablish by competent written proof that particular Confidential Information: (i) was in the public domain at the time of disclosure to the recipientparty; or later became part of the public domain through no act or omission of the recipient party, its employees, agents, successors or assigns; or(ii) was lawfully disclosed to the recipient party by a third party having the right to disclose it to the recipient party; or (iii) was already known bythe recipient party at the time of disclosure; or (iv) was independently developed by the recipient party without use of the disclosing partysConfidential Information; or (iv) is required by law, court order or regulation to be disclosed, provided that the recipient party so obligated todisclose the Confidential Information shall promptly notify the disclosing party of such requirement and provide the disclosing party anopportunity to challenge or limit the disclosure requirement and to seek confidential treatment or protection order, and that the ConfidentialInformation so disclosed shall remain otherwise subject to the confidentiality and non-use obligations set forth above in this section. ParticularConfidential Information shall not be deemed to come under any of the above exceptions merely because it is embraced by more general informationthat is or becomes subject to any of the above exceptions.5.2 Subject to full compliance with Section 5.3 below, either party may disclose the other party’s Confidential Information to its employees,consultants and affiliates who have a need to know such information in order to satisfy such Parties obligations under this Agreement. Suchemployees, consultants and affiliates shall be required to agree to maintain the confidentiality of such information pursuant to terms no lessrestrictive that the ones set forth herein.5.3 Each Party shall protect the other partys Confidential Information with at least the same degree of care as it uses to protect its ownconfidential information, but at no time less than a reasonable degree of care. This obligation will exist while this Agreement is in force and for aperiod of five (5) years thereafter.5.4 Data Privacy and Security Laws. WPD and its subsidiaries (if any) will at all times during the Term be in material compliance with allapplicable data privacy and security laws and regulations, and WPD and its subsidiaries (if any) have taken or will take commercially reasonableactions to comply with the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679) and all other applicable laws andregulations with respect to Personal Data (defined below) that have been announced as of the date hereof as becoming effective within 12 monthsafter the date hereof, and for which any non-compliance with same would be reasonably likely to create a material liability (collectively, the “PrivacyLaws”). To WPD’s knowledge, WPD and its subsidiaries (if any) have been and currently are in material compliance with the GDPR. To ensurematerial compliance with the Privacy Laws, WPD and its subsidiaries (if any) have taken, and currently take, commercially reasonable stepsreasonably designed to ensure compliance in all material respects with Privacy Laws relating to data privacy and security and the collection,storage, use, disclosure, handling, and analysis of Personal Data that WPD has collected, and collects, or is in WPD’s possession or will be inWPD’s possession during the Term. “Personal Data” means "personal data" as defined by GDPR.ARTICLE 6TERM AND TERMINATION6.1 The term of this Agreement will commence on the Effective Date and remain in full force and effect until the expiration of the SublicenseAgreement, unless earlier termination by pursuant to the terms of this Agreement (“Term”).6.2 Subject to any rights herein which survive termination, this Agreement will earlier terminate in its entirety: (i) upon thirty (30) calendardays written notice from either party if the other party materially breaches this Agreement, unless before the end of such thirty (30) calendar daynotice period, the breaching party has cured the material default or breach to the non-breaching party’s reasonable satisfaction; or (ii) at any timeby mutual written agreement between the Parties, subject to any terms herein which survive termination.3Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020ARTICLE 7REPRESENTATIONS, WARRANTIES AND COVENANTS7.1 Each Party represents and warrants that:7.1.1 it is duly organized and validly existing under the laws of its state or country of incorporation, and has full corporate powerand authority to enter into this Agreement and to carry out the provisions hereof;7.1.2 it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the personexecuting this Agreement on its behalf has been duly authorized to do so by all requisite corporate action;7.1.3 this Agreement is legally binding upon it and enforceable in accordance with its terms; that the execution, delivery andperformance of this Agreement by it does not conflict with any Agreement, instrument or understanding, oral or written, to which it is a party or bywhich it may be bound, nor violate any material law or regulation of any governmental entity having jurisdiction over it; and7.1.4 it has not granted, and will not grant during the term of the Agreement, any right to any third party that would conflict withthe rights granted to the other Party hereunder;7.1.5 that it has (or will have at the time performance is due) maintained, and will maintain, and keep in full force and effect, allagreements, permits and licenses necessary to perform its obligations hereunder; and in complying with the terms and conditions of thisAgreement and carrying out any obligations hereunder, it will comply (and it will ensure that its subcontractors comply) with all applicable laws,regulations, ordinances, statutes, and decrees or proclamations of all governmental entities having jurisdiction over such Party.7.2 U.S. FCPA Compliance. WPD hereby agrees to at all times comply with the U.S. Foreign Corrupt Practices Act of 1977, as amended (the“FCPA”), and WPD shall establish, institute and maintain policies and procedures designed to ensure that:7.2.1 no agent, employee or affiliate of WPD, or any of its affiliates, takes any action, directly or indirectly, that would result in aviolation by such person of the FCPA or any other anti-bribery or anti-corruption law, rule or regulation of similar purpose and scope, including,without limitation, making use of the U.S. mails or any means or instrumentality of interstate commerce in furtherance of an unlawful offer, payment,promise to pay or authorization of the unlawful payment of any money, or other property, gift, promise to give, or authorization of the giving ofanything of value to any "foreign official" or any foreign political party or official thereof, of any candidate for any foreign office or any candidatefor foreign political office, in contravention of the FCPA;7.2.2 WPD, and its affiliates, shall at all times keep books, records and accounts which, in reasonable detail, accurately and fairlyreflect the transactions and dispositions of their assets and maintain a system of internal accounting controls sufficient to provide reasonableassurances that transactions are properly authorized and recorded;7.2.3 WPD shall, and shall cause its respective affiliates, to permit CNS and its respective designated representatives, atreasonable times and upon reasonable prior notice to such parties, to review the books and records of WPD and any of its affiliates and to discussthe affairs, finances and condition of such party and any of its affiliates with the officers of such entities and any of their affiliates in relation totheir compliance with this section, as applicable.7.2.4 WPD understands and agrees that CNS may terminate this Agreement immediately and without any early terminationpenalty in the event that WPD, or any of its affiliates, materially violates the FCPA or any other anti-bribery or anti-corruption law. WPDunderstands and agrees that, if WPD, or any of its affiliates, intends to use foreign subcontractors to provide any services pursuant to thisAgreement, such party and each of its affiliates is prohibited from engaging or using subcontractors for performance of services under thisAgreement without prior and express authorization, in writing, by CNS. If WPD, or any of its affiliates, is authorized to engage or usesubcontractors for such work, such party and each of its affiliates so involved agrees to obtain a commitment from the subcontractor to complywith the FCPA and any other anti-bribery or anti-corruption law.4Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020ARTICLE 8 INDEMNIFICATION8.1 WPD hereby agrees to hold harmless and indemnify CNS, its officers, affiliates, employees, and agents (the “CNS Indemnitees”) fromand against any and all third party claims, demands, causes of actions, costs of suit and reasonable and documented attorney’s fees (collectively“Claims”) caused by, arising out of, or resulting from WPD’s, its employees, agents’, affiliates’, licensees’, sublicensees’ or subcontractors’ (i)negligence or willful misconduct; (ii) breach of any warranty or representations set forth herein; (iii) breach or alleged breach of third partyintellectual property rights; and (iv) use or sale of Development Products.ARTICLE 9MISCELLANEOUS9.1 The Parties shall execute and deliver any and all additional papers, documents, and other instruments and shall do any and all furtheracts and things reasonably necessary, if any, in connection with the performance of its obligation hereunder to carry out the intent of thisAgreement.9.2 This Agreement contains the entire understanding of the Parties, and supersedes all prior agreements and understandings between theParties. This Agreement may be amended only by a written instrument signed by the Parties.9.3 The waiver by any Party of any terms or condition of this Agreement, or any part hereof, shall not be deemed a waiver of any otherterm or condition of this Termination Agreement, or of any later breach of this Agreement.9.4 Any notice required by this Agreement will be given by personal delivery (including delivery by reputable messenger services such asFederal Express) or by prepaid, first class, certified mail, return receipt requested, addressed to:If to WPD:If to CNS:WPD Pharmaceuticals sp. z o.oCNS Pharmaceuticals, Inc.Attention: CEOAttention: CEOul. Żwirki i Wigury 1012100 West Loop South, Suite 90002-089 Warszawa, PolandHouston, TX 770279.5 The Article and Section captions in this Agreement have been inserted as a matter of convenience and are not part of this TerminationAgreement. References to or “dollars” means United States dollars.9.6 This Agreement may be executed in counterparts, all of which together shall constitute a single agreement.9.7 If any provision of this Agreement or application thereof to anyone is adjudicated to be invalid or unenforceable, such invalidity orunenforceability shall not affect any provision or application of this Agreement which can be given effect without the invalid or unenforceableprovision or application, and shall not invalidate or render unenforceable such provision or application. Further, the judicial or other competentauthority making such determination shall have the power to limit, construe or reduce the duration, scope, activity and/or area of such provision,and/or delete specific words or phrases as necessary to render, such provision enforceable.9.8 This Agreement will be governed by, construed and enforced in accordance with the laws of the State of Texas. Any dispute betweenthe Parties regarding or related to this Agreement shall be litigated in the courts located in Houston, Texas, and WPD agrees not to challengepersonal jurisdiction in that forum.IN WITNESS WHEREOF, the Parties hereto have executed this Agreement by their duly authorized representatives with full right, powerand authority to enter into and perform under this Agreement.CNS Pharmaceuticals, Inc.By____/s/ John Climaco___________________John Climaco, CEOWPD Pharmaceuticals SP. z o.o.By__/s/ Mariusz Olejniczak___________Mariusz Olejniczak, President5Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020